Key terms
About NPCE
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NPCE news
Mar 07
1:01am ET
Neuropace, Inc.’s New Economy & Political Environment Risk – A Cause for Worry?
Mar 06
11:15pm ET
NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers
Mar 06
9:13am ET
NeuroPace price target raised to $13 from $9 at Morgan Stanley
Mar 06
8:54am ET
NeuroPace price target raised to $20 from $17 at Lake Street
Mar 06
6:28am ET
NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns
Mar 05
4:17pm ET
NeuroPace sees FY24 revenue $73M-$77M, consensus $74.6M
Mar 05
4:15pm ET
NeuroPace reports Q4 EPS (23c), consensus (31c)
Feb 22
6:40am ET
NeuroPace price target raised to $16 from $9 at Wells Fargo
Feb 08
4:56am ET
NeuroPace Announces Chief Legal Officer Irina Ridley’s Departure
Jan 30
6:17am ET
NeuroPace initiated with an Outperform at Leerink
Jan 24
8:30am ET
Three new option listings on January 24th
Jan 09
8:54am ET
NeuroPace price target raised to $17 from $12 at Lake Street
Jan 09
5:11am ET
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Alignment Healthcare (ALHC) and 10x Genomics (TXG)
Jan 08
7:15am ET
NeuroPace sees FY23 revenue $64.9M-$65.4M, consensus $63.01M
Jan 08
7:15am ET
NeuroPace reports preliminary Q4 revenue $17.5M-$18M, consensus $15.79M
Dec 27
9:16am ET
NeuroPace Stock Poised for Continued Growth: Buy Rating Reaffirmed Amid Operational Successes and Market Expansion
Dec 27
9:10am ET
NeuroPace ‘primed for continued outperformance’ in 2024, says Lake Street
Dec 22
5:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)
Dec 21
9:15am ET
Buy Rating on NeuroPace: Expanding Market Reach with RNS System Label Extension and Rapid Trial Progress
Dec 21
7:10am ET
NeuroPace announces early completion of patient enrollment in NAUTILUS study
No recent news articles are available for NPCE
No recent press releases are available for NPCE
NPCE Financials
Key terms
Ad Feedback
NPCE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NPCE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range